SG11202007702UA - Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases - Google Patents
Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseasesInfo
- Publication number
- SG11202007702UA SG11202007702UA SG11202007702UA SG11202007702UA SG11202007702UA SG 11202007702U A SG11202007702U A SG 11202007702UA SG 11202007702U A SG11202007702U A SG 11202007702UA SG 11202007702U A SG11202007702U A SG 11202007702UA SG 11202007702U A SG11202007702U A SG 11202007702UA
- Authority
- SG
- Singapore
- Prior art keywords
- flt3l
- fms
- antibodies
- tyrosine kinase
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630571P | 2018-02-14 | 2018-02-14 | |
PCT/US2019/017877 WO2019160976A1 (en) | 2018-02-14 | 2019-02-13 | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007702UA true SG11202007702UA (en) | 2020-09-29 |
Family
ID=67619040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007702UA SG11202007702UA (en) | 2018-02-14 | 2019-02-13 | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
Country Status (13)
Country | Link |
---|---|
US (2) | US11512127B2 (en) |
EP (1) | EP3752195A4 (en) |
JP (2) | JP2021513357A (en) |
KR (1) | KR20200135331A (en) |
CN (1) | CN111989117A (en) |
AU (1) | AU2019222705A1 (en) |
BR (1) | BR112020016400A2 (en) |
CA (1) | CA3091184A1 (en) |
CL (1) | CL2020002088A1 (en) |
IL (1) | IL276598A (en) |
MX (1) | MX2020008479A (en) |
SG (1) | SG11202007702UA (en) |
WO (1) | WO2019160976A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3752195A4 (en) * | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
JPS5896026A (en) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | Novel urokinase derivative, its preparation and thrombolytic agent containing the same |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP0229046B1 (en) | 1985-03-30 | 1994-05-04 | BALLIVET, Marc | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
DE3675588D1 (en) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE). |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (en) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | Method for enhancing glycoprotein stability. |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992003461A1 (en) | 1990-08-24 | 1992-03-05 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
DE69131017T2 (en) | 1990-12-20 | 1999-07-15 | Ixsys Inc | OPTIMIZATION OF BINDING PROTEINS |
DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
DK1024191T3 (en) | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
ES2202310T3 (en) | 1991-12-13 | 2004-04-01 | Xoma Corporation | METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7534867B1 (en) | 1993-05-19 | 2009-05-19 | Schering Corporation | Purified mammalian Flt3 ligands; agonists; antagonists |
US7045128B2 (en) * | 1993-05-24 | 2006-05-16 | Immunex Corporation | Antibodies against flt3-ligand |
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
US7264963B1 (en) | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
WO1999006834A2 (en) | 1997-08-04 | 1999-02-11 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
WO2001002588A2 (en) | 1999-07-02 | 2001-01-11 | Morphosys Ag | Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
CN101612402A (en) * | 2001-01-09 | 2009-12-30 | 贝勒研究院 | The purposes of interferon antagonist and Flt3L antagonist |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
WO2004003144A2 (en) | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
MXPA05004712A (en) | 2002-11-07 | 2005-11-23 | Immunogen Inc | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same. |
WO2006020145A2 (en) | 2004-07-19 | 2006-02-23 | The Johns Hopkins University | Flt3 inhibitors for immune suppression |
CN101952454B (en) | 2008-02-08 | 2014-06-04 | 米迪缪尼有限公司 | Anti-IFNAR1 antibodies with reduced Fc ligand affinity |
US20130156764A1 (en) * | 2010-03-12 | 2013-06-20 | The Johns Hopkins University | Neutralization of flt3 ligand as a leukemia therapy |
US9415118B2 (en) | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
JP2017525760A (en) * | 2014-08-15 | 2017-09-07 | ジェネクシン・インコーポレイテッドGenexine, Inc. | How to treat cervical cancer |
EP3752195A4 (en) | 2018-02-14 | 2021-11-17 | Viela Bio, Inc. | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases |
-
2019
- 2019-02-13 EP EP19754925.6A patent/EP3752195A4/en active Pending
- 2019-02-13 CN CN201980013516.0A patent/CN111989117A/en active Pending
- 2019-02-13 SG SG11202007702UA patent/SG11202007702UA/en unknown
- 2019-02-13 MX MX2020008479A patent/MX2020008479A/en unknown
- 2019-02-13 CA CA3091184A patent/CA3091184A1/en active Pending
- 2019-02-13 KR KR1020207026493A patent/KR20200135331A/en unknown
- 2019-02-13 BR BR112020016400-3A patent/BR112020016400A2/en unknown
- 2019-02-13 WO PCT/US2019/017877 patent/WO2019160976A1/en unknown
- 2019-02-13 JP JP2020543802A patent/JP2021513357A/en active Pending
- 2019-02-13 AU AU2019222705A patent/AU2019222705A1/en active Pending
- 2019-02-13 US US16/969,774 patent/US11512127B2/en active Active
-
2020
- 2020-08-09 IL IL276598A patent/IL276598A/en unknown
- 2020-08-12 CL CL2020002088A patent/CL2020002088A1/en unknown
-
2022
- 2022-07-21 US US17/814,075 patent/US20230056815A1/en active Pending
-
2023
- 2023-07-21 JP JP2023118763A patent/JP2023139148A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020008479A (en) | 2020-11-24 |
IL276598A (en) | 2020-09-30 |
BR112020016400A2 (en) | 2020-12-15 |
RU2020129978A (en) | 2022-03-14 |
US20210002360A1 (en) | 2021-01-07 |
US11512127B2 (en) | 2022-11-29 |
KR20200135331A (en) | 2020-12-02 |
CA3091184A1 (en) | 2019-08-22 |
WO2019160976A1 (en) | 2019-08-22 |
CL2020002088A1 (en) | 2020-12-11 |
JP2021513357A (en) | 2021-05-27 |
US20230056815A1 (en) | 2023-02-23 |
CN111989117A (en) | 2020-11-24 |
AU2019222705A1 (en) | 2020-10-01 |
EP3752195A1 (en) | 2020-12-23 |
JP2023139148A (en) | 2023-10-03 |
EP3752195A4 (en) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46113A (en) | ANTIBODIES DIRECTED AGAINST T-LYMPHOCYTE IMMUNOGLOBULIN AND MUCINE PROTEIN 3 (TIM-3) | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
IL285182A (en) | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) | |
MA41414A (en) | ICOS AGONIST BINDING PROTEINS | |
IL281962A (en) | Il-12 heterodimeric fc-fusion proteins | |
MA53835A (en) | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS FOR THE P.E. TREATMENT OF INFLAMMATORY DISEASES | |
DK3293202T3 (en) | ANTI HUMAN INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN (IL1RAP) ANTIBODIES AND USES THEREOF | |
WO2013188448A3 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
HK1246684A1 (en) | Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species | |
SG10201913858WA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
MA52910A (en) | PRE-FUSION PROTEIN F OF RSV SOLUBLE AND STABILIZED FOR USE IN THE PROPHYLAXIS OF RSV INFECTION | |
EA201790438A1 (en) | ANTIGEN-BINDING PROTEINS THAT CONNECT WITH CXCR5 | |
WO2016094566A3 (en) | Blood brain barrier receptor antibodies and methods of use | |
GB2550559B (en) | Methods, systems and apparatus for control of parasite infestation in aquatic animals | |
SG11202106498XA (en) | Anti-ctla4 antibodies and methods of use thereof | |
PH12019501605A1 (en) | Glucagon receptor binding proteins and methods of use thereof | |
PL3659433T3 (en) | System for analysis of animal excrement images | |
IL276598A (en) | Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases | |
MA53614A (en) | PROTEIN FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
MX2021002289A (en) | Flt3l-based chimeric proteins. | |
IL266769A (en) | Monoclonal antibodies specific for fgfr1 and their preparation | |
EP3759470C0 (en) | System for use in the detection of binding affinities | |
FR3005164B1 (en) | DEVICE FOR THE PREPARATION OF BIOLOGICAL SAMPLE | |
EP3641813A4 (en) | Il17a antibodies and antagonists for veterinary use | |
EP3785017A4 (en) | Collection systems for flow cytometrically sorted samples and methods of using the same |